Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 19Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Sarcoma 7Nasopharyngeal Carcinoma 2Liposarcoma 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Melanoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 7Cyclophosphamide 6Nivolumab 4fludarabine 3spartalizumab 2aldesleukin 2Trastuzumab 2Standard of Care 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Irinotecan 2Ipilimumab 2Gemcitabine 2zanidatamab 1vocimagene amiretrorepvec 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1toripalimab 1tislelizumab 1tinostamustine 1talazoparib 1sarilumab 1sargramostim 1regorafenib 1pexidartinib 1pertuzumab 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × toripalimab × Sarcoma × Clear all
NCT05955105 2024-05-21

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Innolake Biopharm

Phase 1/2 Recruiting
200 enrolled
BreastDermatologicGynecologicHead & NeckSarcomaThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡